GOVX

• 

  GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation

  3:42 PM|September 19, 2018

  Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis ATLANTA, GA, Sept. 19, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a research article describing a study funded by the Gates Foundation.  In the article, “Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model”, published at Gates Open Research1, the authors discussed their review of product development pipelines for 35

  Read more
• 

  GeoVax Awarded NIH Grant for Novel Zika Vaccine

  1:25 PM|May 24, 2018

  ATLANTA, GA, , May 24, 2018 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its novel Zika vaccine development program. The grant award of $300,000 will fund the second year of a two-year project period with a total budget of $600,000.

  Read more
• 

  GeoVax and ViaMune to Collaborate on Cancer Immunotherapy Program

  4:10 PM|November 7, 2016

  ATLANTA, GA–(Marketwired – Nov 7, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX) announced today its collaboration with ViaMune, Inc. for the co-development of each company’s cancer immunotherapy programs. Both companies’ products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumor types. Due to overexpression and/or aberrant glycosylation of MUC1, this “tumor-associated antigen” (TAA) is often recognized as abnormal by patients’ immune system but is not sufficiently immunogenic

  Read more
• 

  GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials

  3:01 PM|August 2, 2016

  Supports Production of the DNA Component of GeoVax’s GOVX-B11 Preventive HIV Vaccine ATLANTA, GA–GOVX, (Marketwired – Aug 2, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that the National Institute of Allergy and Infectious Diseases, (NIAID) part of the National Institutes of Health (NIH) has awarded it a Staged Vaccine Development contract to further develop GeoVax’s preventive HIV vaccine (GOVX-B11) and to manufacture the DNA component of GOVX-B11 for use in advanced human

  Read more
• 

  GeoVax Awarded NIH Grant for HIV Vaccine Program

  1:44 PM|June 29, 2016

  Supports Development of a Vaccine to Prevent Clade C HIV Prevalent in the Developing World ATLANTA, GA–GOVX, (Marketwired – Jun 29, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in the development of human vaccines, announced today it has received a Notice of Award from the U.S. National Institutes of Health (NIH) for a Small Business Innovative Research (SBIR) grant in support of its clade C HIV vaccine development program for Africa. The grant award of $294,038

  Read more
• 

  GeoVax to Develop Vaccine Against Zika Virus

  3:23 PM|February 3, 2016

  Collaboration With University of Georgia Infectious Disease Researchers Will Speed Development ATLANTA, GA– GOVX, (Marketwired – Feb 3, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has begun a program to develop a vaccine for the prevention of Zika virus infections using its novel MVA-VLP vaccine platform. The company believes that it can rapidly advance a vaccine candidate to human clinical testing. On February 1, 2016, the World Health Organization (WHO)

  Read more